USD 1.07
(-3.6%)
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2023 | 30.65 Million USD | -27.12% |
2022 | 21.4 Million USD | -12.86% |
2021 | 24.55 Million USD | 12.35% |
2020 | 21.86 Million USD | 70.28% |
2019 | 12.83 Million USD | -10.08% |
2018 | 14.27 Million USD | -12.5% |
2017 | 16.31 Million USD | -21.34% |
2016 | 20.74 Million USD | 28.51% |
2015 | 16.14 Million USD | 84.72% |
2014 | 8.73 Million USD | -12.32% |
2013 | 9.96 Million USD | 42.85% |
2012 | 6.97 Million USD | 0.0% |
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2024 Q1 | 1.79 Million USD | 0.47% |
2024 Q2 | 1.61 Million USD | -10.0% |
2023 FY | 15.59 Million USD | -27.12% |
2023 Q4 | 1.78 Million USD | -49.95% |
2023 Q1 | 5.26 Million USD | 10.83% |
2023 Q2 | 4.97 Million USD | -5.49% |
2023 Q3 | 3.57 Million USD | -28.17% |
2022 Q1 | 5.99 Million USD | -7.62% |
2022 Q4 | 4.74 Million USD | -6.58% |
2022 FY | 21.4 Million USD | -12.86% |
2022 Q3 | 5.08 Million USD | -8.86% |
2022 Q2 | 5.57 Million USD | -6.93% |
2021 Q4 | 6.48 Million USD | 18.51% |
2021 Q1 | 6.37 Million USD | -0.71% |
2021 FY | 24.55 Million USD | 12.35% |
2021 Q2 | 6.35 Million USD | -0.35% |
2021 Q3 | 5.47 Million USD | -13.85% |
2020 FY | 21.86 Million USD | 70.28% |
2020 Q4 | 6.42 Million USD | 12.22% |
2020 Q2 | 6.51 Million USD | 103.5% |
2020 Q3 | 5.72 Million USD | -12.16% |
2020 Q1 | 3.2 Million USD | 17.47% |
2019 FY | 12.83 Million USD | -10.08% |
2019 Q1 | 3.89 Million USD | -1.97% |
2019 Q4 | 2.72 Million USD | -11.44% |
2019 Q3 | 3.07 Million USD | -2.01% |
2019 Q2 | 3.13 Million USD | -19.41% |
2018 Q4 | 3.97 Million USD | 17.2% |
2018 Q3 | 3.39 Million USD | -4.79% |
2018 Q1 | 3.35 Million USD | 2.97% |
2018 FY | 14.27 Million USD | -12.5% |
2018 Q2 | 3.56 Million USD | 6.3% |
2017 FY | 16.31 Million USD | -21.34% |
2017 Q4 | 3.25 Million USD | -5.51% |
2017 Q3 | 3.44 Million USD | -22.11% |
2017 Q2 | 4.42 Million USD | -14.92% |
2017 Q1 | 5.19 Million USD | -0.6% |
2016 Q1 | 4.89 Million USD | -11.17% |
2016 FY | 20.74 Million USD | 28.51% |
2016 Q4 | 5.22 Million USD | 2.25% |
2016 Q3 | 5.11 Million USD | -10.28% |
2016 Q2 | 5.69 Million USD | 16.53% |
2015 Q2 | 3.32 Million USD | 19.11% |
2015 Q1 | 2.79 Million USD | 31.35% |
2015 Q3 | 4.49 Million USD | 35.3% |
2015 Q4 | 5.5 Million USD | 22.36% |
2015 FY | 16.14 Million USD | 84.72% |
2014 Q1 | 2.05 Million USD | 72.94% |
2014 Q4 | 2.12 Million USD | -2.73% |
2014 Q3 | 2.18 Million USD | -5.68% |
2014 FY | 8.73 Million USD | -12.32% |
2014 Q2 | 2.31 Million USD | 12.73% |
2013 Q4 | 1.18 Million USD | 0.0% |
2013 FY | 9.96 Million USD | 42.85% |
2012 FY | 6.97 Million USD | 0.0% |
Name | Operating Expenses | Operating Expenses Difference |
---|---|---|
Bionano Genomics, Inc. | 148.99 Million USD | 79.423% |
Prenetics Global Limited | 60.73 Million USD | 49.523% |
Star Equity Holdings, Inc. | 16.27 Million USD | -88.409% |
CareDx, Inc | 277.76 Million USD | 88.963% |
Exact Sciences Corporation | 2.06 Billion USD | 98.512% |
Exagen Inc. | 52.29 Million USD | 41.373% |
Inotiv, Inc. | 246.9 Million USD | 87.583% |
Guardant Health, Inc. | 901.62 Million USD | 96.6% |
Biodesix, Inc. | 77.41 Million USD | 60.4% |
BioNexus Gene Lab Corp. | 3.92 Million USD | -681.476% |
Precipio, Inc. | 13.63 Million USD | -124.798% |
iSpecimen Inc. | 16.27 Million USD | -88.348% |
Natera, Inc. | 938.98 Million USD | 96.735% |
Aspira Women's Health Inc. | 24.11 Million USD | -27.138% |
Standard BioTools Inc. | 113.48 Million USD | 72.986% |
23andMe Holding Co. | 420.73 Million USD | 92.713% |
Castle Biosciences, Inc. | 242.78 Million USD | 87.372% |
Personalis, Inc. | 128.14 Million USD | 76.075% |
Aclaris Therapeutics, Inc. | 110.52 Million USD | 72.262% |
Applied DNA Sciences, Inc. | 16.48 Million USD | -85.955% |
T2 Biosystems, Inc. | 41.49 Million USD | 26.115% |
Myriad Genetics, Inc. | 600.1 Million USD | 94.891% |
ICON Public Limited Company | 755.64 Million USD | 95.943% |
NeoGenomics, Inc. | 341.25 Million USD | 91.016% |
Star Equity Holdings, Inc. | 16.27 Million USD | -88.409% |
IDEXX Laboratories, Inc. | 1.09 Billion USD | 97.195% |
RadNet, Inc. | 268.87 Million USD | 88.598% |
MDxHealth SA | 71.25 Million USD | 56.975% |
Psychemedics Corporation | 11.33 Million USD | -170.496% |
Illumina, Inc. | 3.81 Billion USD | 99.196% |
Check-Cap Ltd. | 19.28 Million USD | -58.957% |
Twist Bioscience Corporation | 354.18 Million USD | 91.344% |
DarioHealth Corp. | 62.17 Million USD | 50.689% |
Fulgent Genetics, Inc. | 171.9 Million USD | 82.166% |
Sera Prognostics, Inc. | 39.91 Million USD | 23.196% |
ENDRA Life Sciences Inc. | 10.52 Million USD | -191.405% |
OPKO Health, Inc. | 574.68 Million USD | 94.665% |
Medpace Holdings, Inc. | 187.68 Million USD | 83.665% |
Neogen Corporation | 405.23 Million USD | 92.435% |
Intelligent Bio Solutions Inc. | 11.7 Million USD | -161.837% |
Prenetics Global Limited | 60.73 Million USD | 49.523% |
Mainz Biomed B.V. | 27.15 Million USD | -12.903% |
bioAffinity Technologies, Inc. | 8.76 Million USD | -249.783% |
Trinity Biotech plc | 46.49 Million USD | 34.062% |
Neuronetics, Inc. | 82.25 Million USD | 62.73% |
Sotera Health Company | 300.46 Million USD | 89.797% |
bioAffinity Technologies, Inc. | 8.76 Million USD | -249.783% |